Date: October 14, 2026
Operational / Strategic Disclosures
Sakar Healthcare Ltd has made significant progress in expanding its global oncology export business across multiple geographies. The company has achieved substantial regulatory milestones and commercial developments:
Regulatory Approvals and Submissions
- 22 Marketing Authorisations (MA) granted from 190 product dossiers submitted to regulatory bodies worldwide
- Approvals cover EU, UK, APAC, Canada, and LatAm regions
- All product dossiers were prepared in-house
Site Variation Approvals
- 11 site variations approved in stringent markets
- Major multinational companies involved include:
- Accord Healthcare Ltd
- Tillomed Laboratories Ltd
- Heumann Pharma GmbH & Co. Generica KG
API Development and Certification
- 2 out of 7 applied for CEPs (Certificate of Suitability) have been approved
- 21 APIs developed in-house
- CEP approvals have encouraged vertical integration of the manufacturing unit
Manufacturing and Commercial Operations
- Commercial supplies have commenced from Sakar's research-driven API-integrated manufacturing facility
- Manufacturing site is EU GMP approved for oncology Finished Dosage Forms (FDF)
- Current business is predominantly skewed toward export of oncology products
Domestic Market Impact Assessment
- Proposed capping on Maximum Retail Price (MRP) for oncology products in domestic market does not impact Sakar's business
- The directive only regulates trade margin, not manufacturers' selling prices and revenues
- Reference: Economic Times, October 12, 2026